Atossa Therapeutics announced that (Z)-endoxifen demonstrated robust inhibition of estrogen receptor signaling in preclinical models of ESR1-mutant breast cancer, a key driver of endocrine resistance. The drug showed superior efficacy compared to other therapies in inhibiting ER activity across major ESR1 mutations. Additionally, the ongoing Phase 2 EVANGELINE trial is testing (Z)-endoxifen combined with goserelin as neoadjuvant therapy in premenopausal women with ER+/HER2- breast cancer, aiming to reduce tumor proliferation. These findings highlight (Z)-endoxifen's potential to address unmet needs in breast cancer treatment, with further clinical data expected from the trial.
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
